Hyphens Pharma International Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Hyphens Pharma International kazanç ve gelirin sırasıyla yıllık 6.7% ve 3.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

6.7%

Kazanç büyüme oranı

6.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	16.7%
Gelir büyüme oranı	3.6%
Gelecekteki özkaynak getirisi	14.7%
Analist kapsamı	Low
Son güncelleme	13 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

Catalist:1J5 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SGD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	211	12	10	N/A	1
12/31/2025	204	12	9	N/A	2
12/31/2024	195	11	1	N/A	2
9/30/2024	197	10	N/A	N/A	N/A
6/30/2024	196	10	1	3	N/A
3/31/2024	185	10	N/A	N/A	N/A
12/31/2023	171	9	4	6	N/A
9/30/2023	156	7	N/A	N/A	N/A
6/30/2023	156	9	9	11	N/A
3/31/2023	156	10	N/A	N/A	N/A
12/31/2022	162	11	16	17	N/A
9/30/2022	156	12	N/A	N/A	N/A
6/30/2022	143	9	7	8	N/A
3/31/2022	132	8	N/A	N/A	N/A
12/31/2021	126	7	5	6	N/A
9/30/2021	126	6	N/A	N/A	N/A
6/30/2021	123	6	6	7	N/A
3/31/2021	126	6	N/A	N/A	N/A
12/31/2020	121	6	3	4	N/A
9/30/2020	126	7	3	4	N/A
6/30/2020	125	8	6	7	N/A
3/31/2020	124	7	8	9	N/A
12/31/2019	119	7	9	9	N/A
9/30/2019	117	6	8	10	N/A
6/30/2019	115	5	9	12	N/A
3/31/2019	117	5	8	11	N/A
12/31/2018	121	5	4	8	N/A
9/30/2018	117	5	0	2	N/A
6/30/2018	117	6	N/A	5	N/A
3/31/2018	115	6	N/A	3	N/A
12/31/2017	113	6	N/A	5	N/A
12/31/2016	101	5	N/A	6	N/A
12/31/2015	78	5	N/A	6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1J5 'nin tahmini kazanç büyümesi (yıllık 6.7% ) tasarruf oranının ( 2.2% ) üzerindedir.

Kazançlar ve Piyasa: 1J5 şirketinin kazançlarının (yıllık 6.7% ) SG pazarından (yıllık 11.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1J5 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 1J5 şirketinin gelirinin (yıllık 3.6% ) SG pazarından (yıllık 3.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1J5 şirketinin gelirinin (yıllık 3.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1J5 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.7 %).

Hyphens Pharma International Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 7.1% to S$0.38

Consensus revenue estimates increase by 10%

Price target decreased by 10% to S$0.34

Price target decreased by 8.9% to S$0.39

Consensus EPS estimates increase by 14%

Price target increased to S$0.41

Recent updates

Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema

Price target increased by 7.1% to S$0.38

First quarter 2024 earnings released

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Final dividend of S$0.0086 announced

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Consensus revenue estimates increase by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2023 earnings released

Price target decreased by 10% to S$0.34

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Second quarter 2023 earnings released

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Price target decreased by 8.9% to S$0.39

Now 23% undervalued after recent price drop

Upcoming dividend of S$0.011 per share at 3.3% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia

Price target increased to S$0.41

Insufficient new directors

Price target increased to S$0.41

Consensus EPS estimates increase by 12%

Second quarter 2022 earnings released

Insufficient new directors

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Price target decreased to S$0.35

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to S$0.35

Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020)

First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020)

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Revenue and earnings miss expectations

Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex

New 90-day low: S$0.32

Price target lowered to S$0.38

New 90-day low: S$0.34

Hyphens Pharma International Limited Announces Board Changes

Analysts update estimates

First half earnings released

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin